SAN DIEGO, November 8, 2017 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) recently begana program to determine the three-dimensional structure of the NR2F6 nuclear receptor. In addition, the Company recently reported that its NR2F6 medicinal chemistry program identified key structural elements in small molecules that make them active and
These two programs are integrally linked. Success in determining the structure of NR2F6 will inform future work on medicinal chemistry, as well as confirm the exact nature of the interaction between Regen's small molecules and NR2F6.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and Lupus.
"The object of the three-dimensional x-ray structure program is to shed light on exactly how our small molecules bind to and modulate NR2F6 activity. Imagine the NR2F6 nuclear receptor (protein) has a specific pocket where activators bind. We don't know the shape of that pocket, although we are beginning to infer it from the key structural elements of our small molecules that bind and activate it. With the actual structural data in hand from the three-dimensional x-ray structure, we will be able to see nuances that will both explain our success so far and will guide us as we make more small molecules. This will also help us improve on the small molecules we have made so far," said Harry Lander, President and Chief Scientific Officer of Regen BioPharma Inc.
"The three-dimensional x-ray structure program, coupled with our medicinal chemistry program will enhance Regen's drug development process. These two programs linked together will give us a much clearer picture of what is actually happening at the molecular level," said David Koos, Ph.D., Chairman and CEO of Regen BioPharma Inc. "That, in turn, will help any of our potential co-development partners feel more comfortable with our mechanism of action."
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is targeting the immunotherapy space, seeking to rapidly advance small molecule immunological therapies to treat cancer and autoimmunity through pre-clinical and Phase I/ II clinical trials. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-702-1404 Phone +1-619-330-2328 Fax
SOURCE Regen BioPharma Inc.
Subscribe to our Free Newsletters!
Tularemia is an uncommon, highly contagious bacterial infection acquired in humans by insect bites ...
Nipah Virus (NiV) or Hendra virus is a deadly virus that spreads via contact with the saliva, ...
Nose Bleeds or Epistaxis are common during summer. Here are simple tips to prevent nasal bleeding ...View All